Skip to content
Screener

Bio-Techne TECH Debt Repayments

Debt Repayments at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
-$2.82B-459%
Danaher logo
DanaherDHR
$1.43B
Bruker logo
BrukerBRKR
$2.3M-84.2%
Revvity logo
RevvityRVTY
$0+100%
Agilent Technologies logo
Agilent TechnologiesA
$1M
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$100K0.0%

Other financials

Income statement

See full
Revenue$311.4M-1.5%
Gross profit$208.3M-2.9%
Operating income$75.5M+95.0%
Net income$51.0M+126%
EPS (diluted)$0.32+129%

Balance sheet

See full
Cash & equivalents$209.8M+49.2%
Total debt$290.3M-31.4%
Total equity$2.1B+3.3%
Total assets$2.6B-3.5%

Cash flow

See full
Operating cash flow$86.7M+111%
CapEx$9.1M-10.2%
Free cash flow$77.6M+150%

Valuation

See full
Market cap$11.22B+43.5%
Enterprise value$11.3B+39.5%
P/E74.9×+16.9×
P/S9.3×+2.9×

Profitability

See full
Gross margin65%-0.8pp
Operating margin14.2%-7.9pp
Net margin10.9%-6.7pp
FCF margin22.3%+4.0pp

Returns & leverage

See full
Return on equity6.5%-3.9pp
Debt / equity0.1×-0.1×
Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfLinesOfCredit.

The source filing: Bio-Techne’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:31 PM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056302
Line itemNine Months Ended / March 31, 2026Nine Months Ended / March 31, 2025
Proceeds from stock option exercises58,19345,513
Repurchases of common stock(24)(175,674)
Borrowings under line-of-credit agreement38,000
Repayments of long-term debt(146,000)(27,000)
Taxes paid on RSUs and net share settlements(10,643)(6,288)
Net cash provided by (used in) financing activities(135,906)(163,453)
Effect of exchange rate changes on cash and cash equivalents(1,985)(1,434)
Net change in cash and cash equivalents47,633(11,121)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Bio-Techne's debt repayments?
Bio-Techne (TECH) reported debt repayments of $60M in Q1 2026.
How has Bio-Techne's debt repayments changed year-over-year?
Bio-Techne's debt repayments increased by 650.0% year-over-year, from $8M to $60M.
What is the long-term trend for Bio-Techne's debt repayments?
Over 3 years (2022 to 2025), Bio-Techne's debt repayments has grown at a -24.0% compound annual growth rate (CAGR), from $175.5M to $77M.
What does debt repayments mean?
Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.

Ask your AI about Bio-Techne's debt repayments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude